Chronic hepatitis C virus infection and lipoprotein metabolism

World Journal of Gastroenterology

Volumn 21, Issue 36, 2015, Pages 10299-10313

  Aizawa, Yoshio ^a   Seki, Nobuyoshi ^a   Nagano, Tomohisa ^a   Abe, Hiroshi ^a  

^a Jikei University Katsushika Medical Center   (Japan)

Author keywords

Apolipoprotein; Dyslipoproteinemia; Hepatitis C virus; Lipo viral particle; Lipoprotein

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN; LIPID; LIPOPROTEIN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; CLASSIFICATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; HUMAN; HUMAN CELL; LIFE CYCLE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; META ANALYSIS (TOPIC); NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; METABOLISM; PATHOGENICITY; VIROLOGY;

ANIMALS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIPOPROTEINS; LIVER; VIRUS INTERNALIZATION;

EID: 84942308771     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i36.10299     Document Type: Review

References (134)

1. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68 [PMID: 25443346 DOI: 10.1016/j.jhep.2014]
3. Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21: 55-65 [PMID: 15736515]
4. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015; 12: 68-78 [PMID: 25761432]
5. Popescu CI, Riva L, Vlaicu O, Farhat R, Rouillé Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) 2014; 3: 892-921 [PMID: 25517881 DOI: 10.3390/biology3040892]
6. Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol 2013; 35: 87-100 [PMID: 23111699 DOI: 10.1007/s00281-012-0356-2]
7. Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD. HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 2011; 55: 1428-1440 [PMID: 21718665 DOI: 10.1016/j.jhep.2011.06.004]
8. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004; 110: 1868-1873 [PMID: 15451808 DOI: 10.1161/01. CIR.0000143041.58692.CC]
9. Giammanco A, Cefalù AB, Noto D, Averna MR. The pathophysiology of intestinal lipoprotein production. Front Physiol 2015; 6: 61 [PMID: 25852563 DOI: 10.3389/fphys.2015.00061]
10. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009; 16: 6-11 [PMID: 19262004]
11. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 2004; 176: 49-56 [PMID: 15306174]
12. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275: 33053-33058 [PMID: 10918065]
13. Grow TE, Fried M. Interchange of apoprotein components between the human plasma high density lipoprotein subclasses HDL2 and HDL3 in vitro. J Biol Chem 1978; 253: 8034-8041 [PMID: 213426]
14. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-5984 [PMID: 12021330]
15. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492 [PMID: 12692249]
16. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011; 9: 32-45 [PMID: 21238945 DOI: 10.1016/j.chom.2010.12.002]
17. Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, Rebhan I, Bartenschlager R, Lohmann V. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog 2013; 9: e1003359 [PMID: 23675303 DOI: 10.1371/journal. ppat.1003359]
18. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097 [PMID: 17721513]
19. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-1205 [PMID: 9037030]
20. Counihan NA, Rawlinson SM, Lindenbach BD. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog 2011; 7: e1002302 [PMID: 22028650 DOI: 10.1371/journal.ppat.1002302]
21. Vieyres G, Dubuisson J, Pietschmann T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses 2014; 6: 1149-1187 [PMID: 24618856 DOI: 10.3390/v6031149]
22. Suzuki R, Matsuda M, Watashi K, Aizaki H, Matsuura Y, Wakita T, Suzuki T. Signal peptidase complex subunit 1 participates in the assembly of hepatitis C virus through an interaction with E2 and NS2. PLoS Pathog 2013; 9: e1003589 [PMID: 24009510 DOI: 10.1371/journal.ppat.1003589]
23. Shanmugam S, Saravanabalaji D, Yi M. Detergent-resistant membrane association of NS2 and E2 during hepatitis C virus replication. J Virol 2015; 89: 4562-4574 [PMID: 25673706 DOI: 10.1128/JVI.00123-15]
24. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-5853 [PMID: 17376867]
25. Boyer A, Dumans A, Beaumont E, Etienne L, Roingeard P, Meunier JC. The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. J Biol Chem 2014; 289: 18904-18913 [PMID: 24838241 DOI: 10.1074/jbc.M113.538256]
26. Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog 2012; 8: e1002466 [PMID: 22241992 DOI: 10.1371/journal.ppat.1002466]
27. Lee JY, Acosta EG, Stoeck IK, Long G, Hiet MS, Mueller B, Fackler OT, Kallis S, Bartenschlager R. Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins. J Virol 2014; 88: 12422-12437 [PMID: 25122793 DOI: 10.1128/JVI.01660-14]
28. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. J Virol 2008; 82: 9647-9656 [PMID: 18667498 DOI: 10.1128/JVI.00914-08]
29. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle-an update. J Hepatol 2014; 61: S3-S13 [PMID: 25443344 DOI: 10.1016/j.jhep.2014.06.031]
30. Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol 2013; 369: 199-218 [PMID: 23463202 DOI: 10.1007/978-3-642-27340-7-8]
31. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103 [PMID: 21146993 DOI: 10.1016/j.tim.2010.11.005]
32. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 2013; 11: 688-700 [PMID: 24018384 DOI: 10.1038/nrmicro3098]
33. Mirandola S, Bowman D, Hussain MM, Alberti A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr Metab (Lond) 2010; 7: 13 [PMID: 20178560 DOI: 10.1186/1743-7075-7-13]
34. Mancone C, Montaldo C, Santangelo L, Di Giacomo C, Costa V, Amicone L, Ippolito G, Pucillo LP, Alonzi T, Tripodi M. Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J Proteome Res 2012; 11: 2786-2797 [PMID: 22443280 DOI: 10.1021/pr201128s]
35. Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 2009; 83: 12680-12691 [PMID: 19793818 DOI: 10.1128/JVI.01476-09]
36. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014; 88: 1433-1446 [PMID: 24173232 DOI: 10.1128/JVI.01815-13]
37. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, Conrads TP, Wang T. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 2008; 48: 1396-1403 [PMID: 18830996 DOI: 10.1002/hep.22508]
38. Nasheri N, Joyce M, Rouleau Y, Yang P, Yao S, Tyrrell DL, Pezacki JP. Modulation of fatty acid synthase enzyme activity and expression during hepatitis C virus replication. Chem Biol 2013; 20: 570-582 [PMID: 23601646 DOI: 10.1016/j.chembiol.2013.03.014]
39. Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 2004; 318: 275-280 [PMID: 15110784]
40. Pollock S, Nichita NB, Böhmer A, Radulescu C, Dwek RA, Zitzmann N. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci USA 2010; 107: 17176-17181 [PMID: 20855621 DOI: 10.1073/pnas.1009445107]
41. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-2566 [PMID: 15699349]
42. Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 2007; 104: 18666-18670 [PMID: 18003907]
43. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH, Reid LM, Lemon SM. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 2014; 20: 927-935 [PMID: 25064127 DOI: 10.1038/nm.3610]
44. Selic Kurincic T, Lesnicar G, Poljak M, Meglic Volkar J, Rajter M, Prah J, Baklan Z, Kotar T, Maticic M. Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3. Intervirology 2014; 57: 23-30 [PMID: 24080608 DOI: 10.1159/000354541]
45. Bader T, Hughes LD, Fazili J, Frost B, Dunnam M, Gonterman A, Madhoun M, Aston CE. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients. J Viral Hepat 2013; 20: 622-627 [PMID: 23910646 DOI: 10.1111/jvh.12085]
46. Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 2013; 28: 51-56 [PMID: 22989264 DOI: 10.1111/j.1440-1746.2012.07267.x]
47. Sidorkiewicz M, Józwiak B, Durys B, Majda-Stanislawska E, Piekarska A, Kosciuk N, Ciechowicz J, Majewska E, Bartkowiak J. Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells. Virus Res 2009; 145: 141-144 [PMID: 19540284 DOI: 10.1016/j.virusres.2009.06.001]
48. Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Fenwick FI, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior nonresponders to combination antiviral therapy-a pilot randomised clinical trial. Liver Int 2014; 34: 737-747 [PMID: 24118830 DOI: 10.1111/liv.12316]
49. Grammatikos G, Farnik H, Bon D, Böhlig A, Bader T, Berg T, Zeuzem S, Herrmann E. The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. J Viral Hepat 2014; 21: 533-541 [PMID: 24943517 DOI: 10.1111/jvh.12274]
50. Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, Jünemann C, Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-3310 [PMID: 19020517 DOI: 10.1038/emboj.2008.244]
51. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98 [PMID: 16459310 DOI: 10.1016/j.cmet.2006.01.005]
52. Janssen HL, Kauppinen S, Hodges MR. HCV infection and miravirsen. N Engl J Med 2013; 369: 878 [PMID: 23984739 DOI: 10.1056/NEJMc1307787]
53. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res 2014; 111: 53-59 [PMID: 25218783 DOI: 10.1016/j.antiviral.2014.08.015]
54. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013; 87: 5270-5286 [PMID: 23449803 DOI: 10.1128/JVI.03022-12]
55. Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, Trépo C, Lotteau V, André P. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006; 87: 2983-2991 [PMID: 16963757]
56. Scholtes C, Ramière C, Rainteau D, Perrin-Cocon L, Wolf C, Humbert L, Carreras M, Guironnet-Paquet A, Zoulim F, Bartenschlager R, Lotteau V, André P, Diaz O. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 2012; 56: 39-48 [PMID: 22290760 DOI: 10.1002/hep.25628]
57. Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, Neely RD, Toms GL, Bassendine MF. Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut 2011; 60: 680-687 [PMID: 20940286 DOI: 10.1136/gut.2010.222133]
58. Merz A, Long G, Hiet MS, Brügger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011; 286: 3018-3032 [PMID: 21056986 DOI: 10.1074/jbc.M110.175018]
59. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-lowdensity lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428 [PMID: 16474148]
60. Fukuhara T, Wada M, Nakamura S, Ono C, Shiokawa M, Yamamoto S, Motomura T, Okamoto T, Okuzaki D, Yamamoto M, Saito I, Wakita T, Koike K, Matsuura Y. Amphipathic ?-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog 2014; 10: e1004534 [PMID: 25502789 DOI: 10.1371/journal.ppat.1004534]
61. Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL, Neely RD, Bassendine MF. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 2010; 139: 1774-1783, 1783.e1-6 [PMID: 20682323 DOI: 10.1053/j.gastro.2010.07.047]
62. Andréo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol 2007; 9: 2445-2456 [PMID: 17517063]
63. Shimizu Y, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. Virology 2010; 407: 152-159 [PMID: 20822787 DOI: 10.1016/j.virol.2010.08.011]
64. Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, Chang TT, Lai MD, Shieh DB, Young KC. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Gut 2013; 62: 1193-1203 [PMID: 22689516 DOI: 10.1136/gutjnl-2011-301798]
65. Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S. Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients. Hepatol Res 2013; 43: 1190-1198 [PMID: 23607715 DOI: 10.1111/hepr.12072]
66. Chatterjee C, Sparks DL. Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. Am J Pathol 2011; 178: 1429-1433 [PMID: 21406176 DOI: 10.1016/j.ajpath.2010.12.050]
67. Boucher J, Ramsamy TA, Braschi S, Sahoo D, Neville TA, Sparks DL. Apolipoprotein A-II regulates HDL stability and affects hepatic lipase association and activity. J Lipid Res 2004; 45: 849-858 [PMID: 14967812]
68. Ramsamy TA, Neville TA, Chauhan BM, Aggarwal D, Sparks DL. Apolipoprotein A-I regulates lipid hydrolysis by hepatic lipase. J Biol Chem 2000; 275: 33480-33486 [PMID: 10944531]
69. Zhu YZ, Qian XJ, Zhao P, Qi ZT. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol 2014; 20: 3457-3467 [PMID: 24707128 DOI: 10.3748/wjg.v20.i13.3457]
70. Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol 2014; 20: 15975-15991 [PMID: 25473151 DOI: 10.3748/wjg.v20.i43.15975]
71. Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci 2015; 129: 63-107 [PMID: 25595801 DOI: 10.1016/bs.pmbts.2014.10.003]
72. Lefèvre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C. Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One 2014; 9: e95550 [PMID: 24751902 DOI: 10.1371/journal.pone.0095550]
73. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012 [PMID: 12867431]
74. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006; 80: 10579-10590 [PMID: 16928753]
75. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012; 86: 7256-7267 [PMID: 22532692 DOI: 10.1128/JVI.07222-11]
76. Koutsoudakis G, Dragun J, Pérez-Del-Pulgar S, Coto-Llerena M, Mensa L, Crespo G, González P, Navasa M, Forns X. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS One 2012; 7: e52651 [PMID: 23300734 DOI: 10.1371/journal. pone.0052651]
77. Xu Y, Martinez P, Séron K, Luo G, Allain F, Dubuisson J, Belouzard S. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 2015; 89: 3846-3858 [PMID: 25609801 DOI: 10.1128/JVI.03647-14]
78. Monazahian M, Böhme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-229 [PMID: 10022791]
79. Wünschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74: 10055-10062 [PMID: 11024134]
80. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55: 998-1007 [PMID: 22121002 DOI: 10.1002/hep.25501]
81. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278: 41624-41630 [PMID: 12913001]
82. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 8063-8071 [PMID: 17507483]
83. Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014; 60: 1508-1518 [PMID: 24797654 DOI: 10.1002/hep.27196]
84. Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2013; 57: 492-504 [PMID: 23081796 DOI: 10.1002/hep.26097]
85. Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 2012; 287: 31242-31257 [PMID: 22767607 DOI: 10.1074/jbc.M112.365924]
86. Sharma NR, Mateu G, Dreux M, Grakoui A, Cosset FL, Melikyan GB. Hepatitis C virus is primed by CD81 protein for low pHdependent fusion. J Biol Chem 2011; 286: 30361-30376 [PMID: 21737455 DOI: 10.1074/jbc.M111.263350]
87. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008; 82: 5007-5020 [PMID: 18337570 DOI: 10.1128/JVI.02286-07]
88. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80: 6964-6972 [PMID: 16809302]
89. Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013; 110: 10777-10782 [PMID: 23754414 DOI: 10.1073/pnas.1301764110]
90. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]
91. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581]
92. Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 2011; 73: 239-259 [PMID: 20809793 DOI: 10.1146/annurevphysiol-012110-142233]
93. Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A. Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection. PLoS One 2014; 9: e92140 [PMID: 24646941 DOI: 10.1371/journal.pone.0092140]
94. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 2004; 45: 1410-1417 [PMID: 15145986]
95. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25: 735-739 [PMID: 9049227]
96. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-2885 [PMID: 12425563]
97. Rojas Á, del Campo JA, Maraver M, Aparcero R, García-Valdecasas M, Diago M, Carmona I, Andrade RJ, Solà R, Romero-Gómez M. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat 2014; 21: 19-24 [PMID: 24188401 DOI: 10.1111/jvh.12209]
98. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-434 [PMID: 11322205]
99. Miyazaki T, Honda A, Ikegami T, Saitoh Y, Hirayama T, Hara T, Doy M, Matsuzaki Y. Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. Hepatol Res 2011; 41: 530-541 [PMID: 21501354 DOI: 10.1111/j.1872-034X.2011.00803.x]
100. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 (Pt 7): 1527-1531 [PMID: 9225025]
101. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2008; 122: 124-131 [PMID: 17764115]
102. Moro?an E, Mihailovici MS, Giu?c? SE, Cojocaru E, Av?d?nei ER, C?runtu ID, Teleman S. Hepatic steatosis background in chronic hepatitis B and C-significance of similarities and differences. Rom J Morphol Embryol 2014; 55: 1041-1047 [PMID: 25607383]
103. Petta S, Vanni E, Bugianesi E, Rosso C, Cabibi D, Cammà C, Di Marco V, Eslam M, Grimaudo S, Macaluso FS, McLeod D, Pipitone RM, Abate ML, Smedile A, George J, Craxì A. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 nonobese subjects with hepatitis C. Aliment Pharmacol Ther 2015; 41: 939-948 [PMID: 25801076 DOI: 10.1111/apt.13169]
104. Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, Cheung R, Wong RJ. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci 2015; 60: 2813-2824 [PMID: 26138651]
105. Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Yang HL, Huang JF, Lin ZY, Chen SC, Yu ML, Chuang WL. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol 2015; 62: 512-518 [PMID: 25457210 DOI: 10.1016/j.jhep.2014.10.011]
106. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res 2014; 44: E137-E144 [PMID: 24125181 DOI: 10.1111/hepr.12258]
107. Nishimura M, Yamamoto H, Yoshida T, Seimiya M, Sawabe Y, Matsushita K, Umemura H, Sogawa K, Takizawa H, Yokosuka O, Nomura F. Decreases in the serum VLDL-TG/non-VLDL-TG ratio from early stages of chronic hepatitis C: alterations in TG-rich lipoprotein levels. PLoS One 2011; 6: e17309 [PMID: 21364889 DOI: 10.1371/journal.pone.0017309]
108. Moriya K, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Yotsuyanagi H, Iino S, Kimura S, Koike K. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003; 25: 371-376 [PMID: 12699847]
109. Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS One 2014; 9: e106376 [PMID: 25184517 DOI: 10.1371/journal.pone.0106376]
110. Ishizaka N, Ishizaka Y, Yamkado M. Atherosclerosis as a possible extrahepatic manifestation of chronic hepatitis C virus infection. Clin Med Insights Cardiol 2014; 8: 1-5 [PMID: 25452704 DOI: 10.4137/CMC.S17069]
111. Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis-a systematic review. Clin Physiol Funct Imaging 2015; Epub ahead of print [PMID: 25620553 DOI: 10.1111/cpf.12229]
112. Nakada Y, Kurosawa H, Tohyama J, Inoue Y, Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J Atheroscler Thromb 2007; 14: 56-64 [PMID: 17485889]
113. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 1999; 142: 309-315 [PMID: 10030382]
114. Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 2015; 62: 763-770 [PMID: 25463543 DOI: 10.1016/j.jhep.2014.11.016]
115. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferonalpha and ribavirin. Aliment Pharmacol Ther 2009; 29: 1282-1290 [PMID: 19392865 DOI: 10.1111/j.1365-2036.2009.04012.x]
116. Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem 2012; 360: 9-14 [PMID: 21879313 DOI: 10.1007/s11010-011-1037-5]
117. Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J Med Virol 2013; 85: 1180-1190 [PMID: 23918536 DOI: 10.1002/jmv.23597]
118. Aizawa Y, Abe H, Yoshizawa K, Ishiguro H, Aida Y, Shimada N, Tsubota A. Dyslipoproteinemia in Chronic HCV Infection. In: Frank S, Kostner G, editors. Lipoproteins-Role in Health and Diseases. Chapter 30. Croatia: InTech, 2012 [DOI: 10.5772/48117]
119. Ghebranious N, Ivacic L, Mallum J, Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res 2005; 33: e149 [PMID: 16204452 DOI: 10.1093/nar/gni155]
120. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-2521 [PMID: 6277903]
121. Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, Burt AD, Donaldson PT. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 2006; 55: 715-718 [PMID: 16299033]
122. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 2010; 84: 12048-12057 [PMID: 20826689 DOI: 10.1128/JVI.01063-10]
123. Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis 2014; 46: 738-743 [PMID: 24880716 DOI: 10.1016/j.dld.2014.05.004]
124. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-463 [PMID: 12143056]
125. Mueller T, Gessner R, Sarrazin C, Graf C, Halangk J, Witt H, Köttgen E, Wiedenmann B, Berg T. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology 2003; 38: 1592; author reply 1592-1593 [PMID: 14647071]
126. Fabris C, Vandelli C, Toniutto P, Minisini R, Colletta C, Falleti E, Smirne C, Pirisi M. Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Gastroenterol Hepatol 2011; 26: 328-333 [PMID: 21261723 DOI: 10.1111/j.1440-1746.2010.06403.x]
127. Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012; 57: 32-38 [PMID: 22414761 DOI: 10.1016/j.jhep.2012.02.017]
128. Seki N, Sugita T, Aida Y, Itagaki M, Ishiguro H, Sutoh S, Abe H, Tsubota A, Matsushima M, Aizawa Y. Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2. Hepatol Int 2014; 8: 550-559 [PMID: 26202760 DOI: 10.1007/s12072-014-9572-2]
129. Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, D'Offizi G, Di Giacomo C, Pucillo LP, Amicone L, Tripodi M, Alonzi T. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent lowdensity lipoproteins. Gut 2011; 60: 378-386 [PMID: 20940285 DOI: 10.1136/gut.2010.211292]
130. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Bréchot C, Barba G. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30: 1064-1076 [PMID: 10498661]
131. Petit JM, Jooste V, Duvillard L, Minello A, Texier V, Galland F, Gambert P, Verges B, Hillon P. Apolipoprotein-AII concentrations are associated with liver steatosis in patients with chronic hepatitis C. Dig Dis Sci 2007; 52: 3431-3434 [PMID: 17436096]
132. Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, Pécheur EI, Cosset FL. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 2007; 282: 32357-32369 [PMID: 17761674]
133. Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000; 275: 37504-37509 [PMID: 10978346]
134. Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int 2012; 6: 475-481 [PMID: 21735316 DOI: 10.1007/s12072-011-9291-x]